POLYCERASOIDOL AND POLYCERASOIDIN DERIVATIVES USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES, TYPE 2 DIABETES MELLITUS, HYPERCHOLESTEROLEMIA, DYSLIPIDEMIAS AND ATHEROSCLEROSIS.

Obesity, especially abdominal obesity, is associated with insulin resistance and fatty acid metabolism, which can lead to the development of metabolic syndrome (MetS) and type 2 diabetes mellitus (T2DM). The treatment of the affected population is mainly carried out through a cocktail of different drugs such as statins, with their associated adverse effects, and hypoglycemic drugs. In recent times, attempts have been made to develop treatments consisting of peroxisome receptor agonists (PPARα and PPARγ), which are very effective but highly toxic. Researchers at the University of Valencia together with the INCLIVA Foundation have developed new compounds based on PRAR agonists that manage to reduce glucose and cholesterol levels with less toxicity than other similar compounds. This lower toxicity opens the way for the development of a more effective and tolerable treatment for these conditions.